Neoadjuvant Dabrafenib Plus Trametinib Has High Pathological Response Rates in Clinical Stage III Melanoma, But Low Rates of Recurrence-Free Survival
Updated analysis of the phase II NeoCombi study
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1548 results
EMA Recommends Extension of Indications for Alectinib to Adjuvant Treatment of Resected ALK-positive NSCLC
New indication concerns adjuvant treatment for ALK-positive NSCLC at high risk of recurrence
Perioperative Treatment with Nivolumab Results in Significantly Longer Event-Free Survival than Chemotherapy in Patients with Resectable NSCLC
Findings from the CheckMate 77T study
Biomarker Analyses in Patients with HER2-positive or HER2-low Gastric and Gastro-oesophageal Junction Cancer Treated with Trastuzumab Deruxtecan
Findings from the exploratory biomarker analyses of the DESTINY-Gastric01 study
Evaluation of Pemigatinib Efficacy in FGFR-Altered Advanced Solid Tumours Led to Identification of New Therapeutic Areas for FGFR Inhibition and Drug Failure Mechanisms
Findings from the FIGHT-207 basket study
EMA Recommends Extension of Indications for Nivolumab to Include First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
It is indicated in combination with cisplatin and gemcitabine
Trastuzumab Deruxtecan Shows Antitumour Activity and Durable Responses in Heavily Pretreated Patients Across Multiple Solid Tumours with Activating HER2 Mutations
Primary results from the DESTINY-PanTumor01 study
FDA Approves Lutetium Lu 177 Dotatate for Paediatric Patients 12 Years and Older with GEP-NETs
Approval is based on pharmacokinetic, dosimetry, and safety data from NETTER-P study in adolescent patients and also on the extrapolation of efficacy outcomes observed in NETTER-1 study which supported the original approval in adult patients
Ibrutinib-Containing Immunochemotherapy in Front-Line Treatment of Young, Medically Fit Patients with Mantle Cell Lymphoma
Findings from the TRIANGLE study
EMA Recommends Granting a Marketing Authorisation for Fruquintinib
It is intended for the treatment of patients with previously treated metastatic colorectal cancer
Feasibility and Safety of Preoperative Treatment with Nivolumab and Relatlimab in Patients with Resectable NSCLC Stages IB, II and IIIA
Findings from the NEOpredict-Lung study
FDA Approves Tisotumab Vedotin-tftv for Recurrent or Metastatic Cervical Cancer
The innovaTV 301 study results fulfill the post-marketing requirement of the previous accelerated approval